<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03424564</url>
  </required_header>
  <id_info>
    <org_study_id>E2007-C086-052</org_study_id>
    <nct_id>NCT03424564</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study of Perampanel in Chinese Healthy Subjects</brief_title>
  <official_title>A Single and Multiple Dose Pharmacokinetic Study of Perampanel in Chinese Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be conducted to evaluate the pharmacokinetics of perampanel following single
      and multiple oral doses in Chinese healthy male and female participants.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 20, 2018</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Single-dose Part: Mean value of the maximum observed concentration (Cmax) postdose of perampanel</measure>
    <time_frame>0-336 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Single-dose Part: Mean value for the time at which the highest drug concentration occurs (tmax) postdose of perampanel</measure>
    <time_frame>0-336 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Single-dose Part: Mean value for area under the concentration-time curve from zero time to 24 hours (AUC[0-24h]) postdose of perampanel</measure>
    <time_frame>0-24 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Single-dose Part: Mean value for area under the concentration-time curve from zero time to time of last quantifiable concentration (AUC[0-t]) postdose of perampanel</measure>
    <time_frame>0-336 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Single-dose Part: Mean value for area under the concentration-time curve from zero time extrapolated to infinite time (AUC[0-inf]) postdose of perampanel</measure>
    <time_frame>0-336 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Single-dose Part: Mean value for the terminal phase rate constant (λz) postdose of perampanel</measure>
    <time_frame>0-336 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Single-dose Part: Mean value for terminal elimination phase half-life (t1/2) postdose of perampanel</measure>
    <time_frame>0-336 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Single-dose Part: Mean value for apparent total clearance following oral administration (CL/F) postdose of perampanel</measure>
    <time_frame>0-336 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Single-dose Part: Mean value for the apparent volume of distribution at terminal phase (Vz/F) postdose of perampanel</measure>
    <time_frame>0-336 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Single-dose Part: Mean residence time (MRT) postdose of perampanel</measure>
    <time_frame>0-336 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple-dose Part: Mean value of Cmax postdose of perampanel on Day 1</measure>
    <time_frame>0-24 hours postdose on Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple-dose Part: Mean minimum observed concentration (Cmin) postdose of perampanel on Day 1</measure>
    <time_frame>0-24 hours postdose on Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple-dose Part: Mean tmax postdose of perampanel on Day 1</measure>
    <time_frame>0-24 hours postdose on Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple-dose Part: Mean AUC(0-24h) postdose of perampanel on Day 1</measure>
    <time_frame>0-24 hours postdose on Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple-dose Part: Mean value of area under the concentration-time curve over the dosing interval on multiple dosing (AUC[0-τ])</measure>
    <time_frame>0-24 hours postdose of perampanel on Day 21</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple-dose Part: Mean value of the average steady-state concentration (Css,av) postdose of perampanel on Day 21</measure>
    <time_frame>0-24 hours postdose on Day 21</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple-dose Part: Mean value of the maximum observed concentration at steady state (Css,max) postdose of perampanel on Day 21</measure>
    <time_frame>0-24 hours postdose on Day 21</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple-dose Part: Mean value of the minimum observed concentration at steady state (Css,min) postdose of perampanel on Day 21</measure>
    <time_frame>0-24 hours postdose on Day 21</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple-dose Part: Mean value of peak-trough fluctuation (PTF) postdose of perampanel on Day 21</measure>
    <time_frame>0-24 hours postdose on Day 21</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple-dose Part: Mean time at which the highest drug concentration occurs at steady state (tss,max) postdose of perampanel on Day 21</measure>
    <time_frame>0-24 hours postdose on Day 21</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple-dose Part: Mean time at which the lowest drug concentration between dosing intervals occurs at steady state (tss,min) postdose of perampanel on Day 21</measure>
    <time_frame>0-24 hours postdose on Day 21</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple-dose Part: Mean value of t1/2 postdose of perampanel on Day 21</measure>
    <time_frame>0-336 hours postdose on Day 21</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple-dose Part: Mean value of apparent total clearance following oral administration at steady state (CLss/F) postdose of perampanel on Day 21</measure>
    <time_frame>0-24 hours postdose on Day 21</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple-dose Part: Mean value of Vz/F postdose of perampanel on Day 21</measure>
    <time_frame>0-336 hours postdose on Day 21</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple-dose Part: Mean value of the accumulation ratio</measure>
    <time_frame>0-24 hours postdose of perampanel on Days 1 and 21</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Perampanel single-dose Part: 2 mg group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single 2 milligrams (mg) dose of perampanel orally under fasted conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Perampanel single-dose Part: 4 mg group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single 4 mg dose of perampanel orally under fasted conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Perampanel single-dose Part: 8 mg group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single 8 mg dose of perampanel orally under fasted conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Perampanel multiple-dose Part</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive multiple oral dose of perampanel (2 milligrams per day [mg/day] from Day 1 to Day 7 and 4 mg/day from Day 8 to Day 21). Fasted condition is required for Days 1 and 21.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Perampanel</intervention_name>
    <description>Oral Tablet</description>
    <arm_group_label>Perampanel single-dose Part: 2 mg group</arm_group_label>
    <arm_group_label>Perampanel single-dose Part: 4 mg group</arm_group_label>
    <arm_group_label>Perampanel single-dose Part: 8 mg group</arm_group_label>
    <arm_group_label>Perampanel multiple-dose Part</arm_group_label>
    <other_name>E2007</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Participants must meet all of the following criteria to be included in this study:

          -  Chinese healthy adult volunteers (males and females)

          -  Non-smoking, male or female age ≥18 years and ≤45 years old at the time of obtaining
             written consent. To be considered non-smokers, participants must have discontinued
             smoking from screening before first dosing.

          -  Participants with a Body Mass Index ≥18.5 and &lt;24.5 kilograms per meters squared at
             screening

          -  Participants who undergo screening within 3 weeks before study treatment and are
             confirmed to be eligible by the investigator

        Exclusion Criteria:

        Participants who meet any of the following criteria will be excluded from this study:

          -  Participants who weigh less than 50 kilograms

          -  Females who are breastfeeding or pregnant at Screening or Baseline

          -  Females of childbearing potential

          -  Clinically significant illness that requires medical treatment within 8 weeks or a
             clinically significant infection that requires medical treatment within 4 weeks before
             first dosing

          -  Evidence of disease that may influence the outcome of the study within 4 weeks before
             first dosing

          -  Any history of gastrointestinal surgery that may affect pharmacokinetic profiles of
             perampanel at Screening

          -  Any clinically abnormal symptom or organ impairment found by medical history at
             Screening, and physical examinations, vital signs, electrocardiogram (ECG) finding, or
             laboratory test results that require medical treatment at Screening

          -  A prolonged QT/corrected QT (QTc) interval (QTc interval for heart rate using
             Fredericia's formula &gt;450 milliseconds) as demonstrated by a repeated ECG at Screening
             or Baseline
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Eisai Trial Site</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 1, 2018</study_first_submitted>
  <study_first_submitted_qc>February 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 7, 2018</study_first_posted>
  <last_update_submitted>May 21, 2018</last_update_submitted>
  <last_update_submitted_qc>May 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Perampanel</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>E2007</keyword>
  <keyword>Chinese</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

